{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/61b8858f0285e100120a440a/69a8a04497f00280f09a1bbc?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Dr. Karin Rosén, Board member of Diamyd Medical – Moderated by Julie Ames from Ventures Accelerated","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b8858f0285e100120a440a/1772658622910-a8bb2810-c6ba-4870-b3f5-d92e49a110a1.jpeg?height=200","description":"<p>How does Nordic life science innovation translate into global impact? In this episode of the SACC New England Podcast, we explore how new discoveries about the immune system are shaping the future of diabetes research.</p><p><br></p><p>Moderator Julie Ames speaks with Dr. Karin Rosén, physician-scientist and board member of Diamyd Medical, a Swedish biotech company developing a therapy designed to help preserve the body’s own insulin production. Together, they discuss the science behind immune tolerance, the company’s ongoing Phase 3 clinical trial, and why the U.S. market plays a critical role in scaling Nordic biotech innovation.</p>","author_name":"The Swedish-American Chamber of Commerce New England "}